São Paulo, December 10, 2025 — Eurofarma was once again one of the main highlights at the Abrafarma Partners of the Year Award (Brazilian Association of Pharmacy and Drugstore Chains), earning recognition in two categories: Manufacturer – Branded Medicine and Products – Generic Medicine: Tadalafil MG. The award recognizes companies that stand out for excellence in relationships and for raising the level of service offered to the pharmaceutical retail sector.

The award ceremony took place last Tuesday, the 9th, in São Paulo, bringing together presidents and executives from the pharmaceutical industry, wholesale, and retail sectors. Andréa Frazão, Medical Prescription Director at Eurofarma, and Donino Scherer, Director of Generics and OTC at the company, represented the commercial areas, reinforcing the company’s strong presence among physicians and pharmacies across the country. The executives also highlighted the company’s mission to bring health to the population through high-quality, affordable medicines.

Eurofarma also received two additional nominations in this 2025 edition: Best Generic Medicine Manufacturer and Best Manufacturer – E-commerce.

To learn more about the company’s recent recognitions across different areas of business, visit: Awards and Recognitions – Eurofarma

 
About Eurofarma

Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people’s quality of life. Focused on generating shared value, the company covers the main pharmaceutical segments, including medical prescription, generics, hospital care, oncology, OTC medicines, personal care, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, its portfolio comprises more than 4,000 SKUs, serving virtually all medical specialties. A leader in medical prescription in Brazil, where it also holds the second position in generics, Eurofarma is present in 24 countries, with full coverage across Latin America and leadership in the region’s retail market. The company also operates in the United States and Africa, employs more than 13,500 people worldwide, and runs 11 manufacturing plants. In 2024, Eurofarma produced 600 million units. In the same year, the company invested more than BRL 800 million in innovation projects and achieved net revenue exceeding BRL 11 billion.